Subject: Vaccines and immunization
Publication date: All
- Disposable-Syringe Jet Injectors
Part of the Technology Updates series, this fact sheet describes PATH's work on designing the next generation of jet injectors.
Publication date: January 2014
Part of series: Technology Updates
- Domestic Refrigerators for Vaccine Storage in Tunisia: Conclusion and Recommendations
This project Optimize document summarizes a laboratory report on performance testing of four models of domestic refrigerators that are available on the Tunisian market. Project Optimize contracted the tests to demonstrate to the government the importance of prequalification of models according to World Health Organization quality, safety, and standards for the storage of vaccines.
Author: Lloyd J, McCarney S, Ouhichi R
Publication date: October 2012
- Dry-Reagent Storage for Disposable Lab-on-Card Diagnosis of Enteric Pathogens
An exploration of one technique for drying reagents onto a microfluidics card. Reagents needed for immunocapture, lysis, and PCR for pathogen capture can be stored in trehalose or trehalose dextran. Presented at the 1st Distributed Diagnosis and Home Healthcare Conference, April 2, 2006; Arlington, VA.
Author: Ramachandran S, Weigl BH, Gerdes JC, et al
Publication date: April 2006
- Efficacy of Standard Methods for Water Testing at a Range of Nonstandard Temperature
Fifteen strains of Escherichia coli from various geographical areas, animal, and soil sources were tested on standard and nonstandard detection assays at temperatures from 23°C to 45°C to test the viability of currently available E. coli tests in low-resource settings. Presented at the American Society for Microbiology Conference, June 1, 2008; Boston, MA.
Author: Allen E, Dillman L, Weigl B
Publication date: June 2008
- Evaluating HPV Vaccination Pilots: Practical Experience From PATH
This unit of the Cervical Cancer Prevention: Practical Experience Series on the RHO Cervical Cancer website provides methods and tools for designing and conducting an evaluation of a human papillomavirus (HPV) vaccination pilot or demonstration project. It also gives practical examples of using the results to refine an HPV vaccine delivery strategy for national scale-up.
Publication date: 2012
- Evaluating HPV Vaccine Delivery Strategies in Vietnam
This report is a synthesis of the project Evaluating HPV Vaccine Delivery Strategies in Vietnam, which aimed to identify appropriate strategies for human papillomavirus (HPV) vaccine delivery in different geographic and socioeconomic conditions. The report summarizes results of both the implementation and research aspects of the project. The document is available as one large file or as four smaller files for easier downloading.
Publication date: December 2010
- Evaluation of Out-of-the-cold-chain Approaches for Improving On-time Delivery of the Hepatitis B Birth Dose in Rural Areas of China
This document summarizes the results of a study of out-of-the-cold-chain approaches for improving on-time delivery of birth doses of the hepatitis B vaccine in rural areas of China.
Publication date: 2006
- Exploring New, Non-replicating Rotavirus Vaccines
This fact sheet summarizes the technical efforts and objectives of PATH's non-replicating rotavirus vaccine (NRRV) project. It outlines the vaccine candidates under evaluation and primary partners, as well as the rationale for the NRRV approach.
Publication date: January 2013
- Fact Sheet: Meningococcal Meningitis
Key facts about meningococcal meningitis, including disease transmission, symptoms, diagnosis, treatment, and prevention; outbreak trends; and global public response.
Publication date: February 2013
- Fighting Malaria Today and Tomorrow: PATH Works With Developing Countries to Achieve a Malaria-Free World
This fact sheet describes PATH's work to eliminate malaria, including expanding the use of lifesaving tools, identifying and developing better diagnostics and drugs, devising new strategies for malaria control, and accelerating the development of malaria vaccines.
Publication date: May 2013
Part of series: Areas of focus fact sheets
- First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
A malaria vaccine, deployed in combination with current malaria-control tools, could play an important role in the future control and eventual elimination of malaria in Africa. This article, published in the New England Journal of Medicine, reports the initial results of an ongoing phase 3 trial of RTS,S/AS01 being conducted at 11 centers in seven African countries.
Publication date: November 2011
- Fragile Lives - Immunization at Risk
Publication date: 2004
- Freeze-Protection of Aluminum-Adjuvanted Vaccines: PATH Formulation Technology
PATH has developed a low-cost and straightforward approach for protecting aluminum-adjuvanted vaccines from irreversible damage that results from freezing. Many current vaccines of importance to global health contain an aluminum-salt adjuvant (such as aluminum hydroxide or aluminum phosphate) and could benefit from this freeze-protection technology. There is no intellectual property barrier for manufacturers wishing to adopt the technology; it has been placed in the public domain. This technical dossier summarizes the rationale for freeze protection, application of the technology to specific vaccines, the data obtained to date, and comments on the likely regulatory pathway for vaccines incorporating the technology.
Publication date: February 2014
- Global Health Technologies Coalition Website
The Global Health Technologies Coalition's website offers information and resources on research and development for new global health tools. It also serves as a clearinghouse of information about coalition activities and global health research and development.
Publication date: 2014
Part of series: Websites
- Global Vaccine Action Plan: 2011-2020
The Global Vaccine Action Plan (GVAP)—endorsed by the 194 Member States of the World Health Assembly in May 2012—is a roadmap to prevent millions of deaths by 2020 through more equitable access to vaccines for people in all communities. The GVAP aims to strengthen routine immunization, introduce new and improved vaccines, and advance research and development for the next generation of vaccines and technologies.
Author: Decade of Vaccines Collaboration
Publication date: May 2012
- Green Supply Chains: A Glimpse into the Future?
This project Optimize evidence brief discusses the rationale for introducing net-zero energy systems into vaccine supply chains and describes the experiences and lessons learned in a demonstration project in Tunisia. Opportunities and challenges are presented and evidence is provided for national and global readers involved in immunization supply chains who may be considering a similar intervention.
Publication date: September 2013
Part of series: Project Optimize evidence brief series
- Guidelines for Implementing Supportive Supervision: A Step-by-Step Guide with Tools to Support Immunization
Publication date: 2003
- Harnessing Solar Energy for Health Needs
Many health facilities in remote areas operate without grid electricity, have unreliable electricity, or find that using electricity is too costly. In these settings, solar energy is a promising solution for powering the storage and transportation of vaccines and heat‐sensitive drugs at controlled temperatures. Project Optimize, a collaboration between the World Health Organization and PATH, has been working with public and private partners on several solar technologies tailored to the following local electrical power conditions: unavailable or unreliable power, intermittent power, and reliable power.
Publication date: July 2012
- A Heat-Stable Hepatitis B Vaccine Formulation
This article, published in Human Vaccines (Human Vaccines 5:8, 1-7; August 2009), details a collaborative effort between PATH, Arecor, and the University of Colorado Denver School of Pharmacy that has resulted in a new formulation for recombinant hepatitis B vaccine that demonstrates improved stability at elevated temperatures. The formulation exhibited 9-week stability at 55°C and was also shown to be stable at both 37°C and 45°C for at least six months. This new vaccine formulation has the potential to be stored at room temperature for part of its shelf life and will help ensure the potency of the vaccine in areas where the cold chain is insufficient.
Author: Jezek J, Chen D, Watson L, et al.
Publication date: August 2009
- Helping Young People Become Youth Advocates for Immunization
Author: Smith T; Wittet S
Publication date: 2000
Part of series: CVP Occasional Papers